Treating Chronic Fatigue Syndrome (ME/CFS): Valtrex (valcyclovir)
Valtrex is an antiviral drug approved to treat genital
herpes infection, herpes zoster (shingles) and herpes labialis (cold sores)
infections. Dr. Martin Lerner of Royal Beaumont Hospital in Royal Oak, Michigan,
is currently investigating its efficacy in chronic fatigue syndrome (ME/CFS)
patients with Epstein-Barr virus infections. Valtrex is converted in the body to
acyclovir which inhibits viral DNA replication. It is produced by
GlaxoSmithKline.
Anti-Virals and Immune Modulators
Translate this page into any language
Valtrex May Work in Chronic Fatigue Syndrome (ME/CFS) Because
it may inhibit the replication of a virus (Epstein-Barr virus (EBV) shown to be
activated in some chronic fatigue syndrome (ME/CFS) patients.
Chronic Fatigue Syndrome (ME/CFS) Studies – Dr.
Lerner's 2002 Valtrex trial resulted in much decreased symptoms and increased
energy and improved ventricular functioning for about 2/3rds of ME/ CFS patients
at 18 months suggests an EBV associated cardiomyopathy may be important
in some patients.
A blinded,
placebo-controlled 2007 study of chronic fatigue syndrome (ME/CFS) patients with
documented Epstein-Barr virus (EBV) reactivation by Dr. Lerner found
Valtrex resulted in increased physical functioning and improved heart
functioning (reduced sinus tachycardias, decreased abnormal cardiac wall
movements) and reduced EBV antibody levels.
Many patients were able to resume normal activities by the end of the 36 month
trial.
Patients with both EBV and cytomegalovirus infections did not improve. This
suggested a different kind of drug treatment was needed for patients with
multiple infections.
A recent study may explain why long time antiviral therapy may be necessary to
successfully fight an EBV infectious (Hoshino 2009). It found that Valacyclovir
reduces cell to cell reinfection but does not effect EBV infected cells. Since
cell to cell reinfection is the chief means EBV has of maintaining itself in the
body very long term antiviral therapy could reduce EBV infection rates simply by
allowing infected B cells to die off over time without being replaced. This can
account for the very longbe replaced over time.
Dig Deeper! EBV and
Chronic Fatigue Syndrome (ME/CFS)
Dig Deeper! Dr. Lerner's Website
Chronic Fatigue Syndrome (ME/CFS) Patients Report –
Patient testimonials are present on
Dr. Lerner’s website; substantial
improvement is generally reported with some returns to complete health. Patient
reports can also be found at Revolution Health.com
Side Effects include nausea, headache, fatigue and
others in some individuals.
The Phoenix Rising website is
compiled by a layman. It is not a substitute for a physician and is for
informational uses only. It does not present complete information on this drug.
Please discuss any treatments in these pages with your physician.
__________________________________________
Hogg, Mathew. Antiviral Drug May Help Some With Chronic Fatigue Syndrome. EI
Resource
Hoshino Yo, Katano D, et. al. Long-term administration of valacyclovir reduces
the number of EBV infected cells. Journal of Virology, published online
September, 2009.
Dr. Lerner’s Chronic Fatigue
Syndrome Treatment Center
Lerner AM, Beqaj SH, Deeter RG, Dworkin HJ, Zervos M, Chang CH, Fitzgerald JT,
Goldstein J, O'Neill W. A six-month trial of valacyclovir in the
Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left
ventricular function. Drugs Today (Barc). 2002 Aug;:549-61. Review.
Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT.Valacyclovir treatment in
Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.
In Vivo. 2007 Sep-Oct;21<5):707-13
RxList the Internet
Drug Index: Valtrex